Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
Cambrex strikes again with acquisition of Avista
by Rick Mullin
November 22, 2018
| A version of this story appeared in
Volume 96, Issue 47
Continuing a string of acquisitions, Cambrex has agreed to acquire Avista Pharma Solutions for $252 million. Avista is owned by Ampersand Capital Partners and operates three facilities in the U.S. and one in Scotland. It engages in a range of pharmaceutical services, including early-stage small-molecule development and testing as well as finished-dosage services. The deal follows Cambrex’s acquisition of Halo Pharma earlier this year, which added final-dosage services to Cambrex’s offerings.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X